PINACIDIL

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Mixture
ATC C02DG01
UNII 7B0ZZH8P2W
EPA CompTox DTXSID4045682

Structure

InChI Key IVVNZDGDKPTYHK-UHFFFAOYSA-N
Smiles CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C
InChI
InChI=1S/C13H19N5/c1-10(13(2,3)4)17-12(16-9-14)18-11-5-7-15-8-6-11/h5-8,10H,1-4H3,(H2,15,16,17,18)

Physicochemical Descriptors

Property Name Value
Molecular Formula C13H19N5
Molecular Weight 245.33
AlogP 2.35
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 73.1
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 18.0

Bioactivity

Mechanism of Action Action Reference
Sulfonylurea receptor 2, Kir6.2 opener OPENER PubMed PubMed
Protein: Sulfonylurea receptor 2, Kir6.2
Description: ATP-binding cassette sub-family C member 9
Organism : Homo sapiens
O60706 ENSG00000069431
Protein: Sulfonylurea receptor 2, Kir6.2
Description: ATP-sensitive inward rectifier potassium channel 11
Organism : Homo sapiens
Q14654 ENSG00000187486
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Voltage-gated ion channel Potassium channels Inwardly rectifying potassium channel
- - - 320 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 91
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
3540 - - 320 -
Assay Description Organism Bioactivity Reference
Binding affinity was determined by displacement of [3H]P1075 from its binding sites in canine cardiac membranes Canis lupus familiaris 320.0 nM
Compound was tested for vasorelaxant activity on the basis of ability to relax endothelium-denuded rat aortic strips toned with 20 mM KCl Rattus norvegicus 380.0 nM
In vitro inhibitory concentration that relaxes KCL induced contraction in rat detrusor strips by 50% Rattus norvegicus 630.0 nM
Inhibitory concentration against methoxamine-induced contractions in rat aorta Rattus norvegicus 59.6 nM
Vasorelaxant potency required to relax methoxamine contracted male Wistar Kyoto rat thoracic aorta Rattus norvegicus 70.0 nM
Vasorelaxant potency required to relax methoxamine contracted male Wistar Kyoto rat thoracic aorta Rattus norvegicus 70.0 nM
Relaxation of phenylephrine precontracted rat isolated aorta rings. Rattus norvegicus 800.0 nM
In vitro inhibition of 30 mM KCl-induced contraction of rat aorta rings. Rattus norvegicus 500.0 nM
Spontaneous relaxant activity in rat aorta precontracted with 30 mM KCl Rattus norvegicus 724.44 nM
Negative logarithm of the molar concentration of compound required to relax rat aorta precontracted with 30 mM KCl by 50% Rattus norvegicus 724.44 nM
Relaxation of rat aorta smooth muscle precontracted with 30 mM KCl (Negative logarithm of molar concentration required) Rattus norvegicus 724.44 nM
Negative logarithm of the molar concentration required to relax rat aorta precontracted with 30 mM KCI by 50% of IA Rattus norvegicus 724.44 nM
Negative logarithm of the molar concentration required to relax rat aorta precontracted with 30 mM KCL by 50% of intrinsic activity Rattus norvegicus 724.44 nM
Negative logarithm of the molar concentration required to relax rat aorta precontracted with 30 mM KCl by 50% of intrinsic activity Rattus norvegicus 724.44 nM
Tested for relaxation of rat aorta smooth muscle precontracted with 30 mM KCI by 50%, activity expresses as negative logarithm of molar concentration Rattus norvegicus 724.44 nM
Concentration required to cause 50% inhibition of spontaneous activity in rat portal vein Rattus norvegicus 63.1 nM
Inhibitory concentration against rat vascular smooth muscle tissue Rattus norvegicus 350.0 nM
Reversal of inhibition of electrical field stimulation-induced neurogenic contractions in New Zealand white rabbit gastric fundus smooth muscle in presence of glibenclamide Oryctolagus cuniculus 32.18 %
Myorelaxant activity in potassium depolarized Wistar rat aorta rings assessed as relaxation of KCl-induced contraction Rattus norvegicus 350.0 nM
Channel opening activity at KATP channel in Wistar rat endothelium-denuded aortic ring assessed as relaxation of KCl-induced contraction Rattus norvegicus 350.0 nM
Myorelaxant effect in KCl-induced precontracted rat aorta ring VSMC Rattus norvegicus 620.0 nM
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 96.43 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 90.66 %
Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction Rattus norvegicus 390.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus -1.94 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli -6.33 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 0.13 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 0.62 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 16.59 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 1.29 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -6.76 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 23.85 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.16 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.16 %

Cross References

Resources Reference
ChEBI 34923
ChEMBL CHEMBL1200338
FDA SRS 7B0ZZH8P2W
Guide to Pharmacology 2412
KEGG C13729
PubChem 55329
SureChEMBL SCHEMBL65786
ZINC ZINC18189761
ChEBI 91706
ChEMBL CHEMBL1159
DrugBank DB06762
DrugCentral 2173
FDA SRS BB4UGO5K0D
Guide to Pharmacology 2412
PubChem 55329
SureChEMBL SCHEMBL65787
ZINC ZINC18189761
CONTENTS